United States: Brexit At Halfway: Pharma And Medical Devices

The object of this Alert is to highlight some practical implications of Brexit for the supply of pharmaceutical products and medical devices in the European Union (EU) and related action items which companies should be considering if they have not done so before.

I. Overall Timing

The United Kingdom (UK) notified its intention to withdraw from the EU pursuant to Article 50 of the Treaty on the Functioning of the European Union on 29 March 2017. Subject to finalisation of the Withdrawal Agreement, under Article 50, the UK's membership of the EU should therefore terminate on 30 March 2019.

On 19 March 2018, the EU and the UK reached an agreement on a transitional arrangement. According to this agreement, the UK commits to remain in the EU Customs Union and retains access to the EU Single Market until 31 December 2020, provided that it abides by EU law.1

This should have the effect of deferring the impact of the changes outlined in this Alert from 30 March 2019 to 31 December 2020.

However, the agreement on the transitional period is still subject to ratification. As a result, pharmaceutical and medical devices companies should treat this development cautiously, and already be addressing their post-Brexit solutions.

For the purposes of this Alert, "EU27" refers to the EU without the UK and, by virtue of various measures under the European Economic Area (EEA) Agreement, includes Iceland, Liechtenstein and Norway.

II. Pharmaceutical Products

(a) UK Participation in the EMA

On 2 March 2018, the UK Prime Minister, Theresa May, delivered a speech on the future of the UK's relationship with the EU, calling for the UK to become an associate member of the European Medicines Agency (EMA). Mrs. May stated that the UK would commit to abiding by the rules of the EMA as well as make appropriate financial contributions to the Medicines Agency.

The European Council, however, quickly appeared to reject the possibility of the UK's participation in the EMA by stating that 'the Union will preserve its autonomy as regards its decision-making, which excludes participation of the United Kingdom as a third-country to EU Institutions, agencies or bodies'.2 As regards the EMA, this statement is in line with the EU regulation on authorisation and supervision of medicinal products, which does not contain a provision for third states to become members or observers of the EMA.3

We will have to see what happens in the future negotiations on the Free Trade Agreement (FTA) on this issue.

In January 2018, the UK Medicines and Healthcare Products Regulatory Agency published an update to pharmaceutical companies on Brexit preparation. The update aims at reassuring pharmaceutical companies that there should be no sudden change to the UK regulatory framework and that pragmatic solutions will be put in place to accommodate companies in implementing any changed requirements.4

In any event, despite the transitional period, the EMA will be relocated from London to Amsterdam, the Netherlands on 30 March 2019 at the latest, in line with the timeline of Article 50.

(b) Current To-Dos and Brexit Related Guidance of EMA and CMDh

The EU rules in the field of medicinal products for human and veterinary use will no longer apply to the UK after 30 March 2019. This has, in particular, the following consequences in the different areas of EU law on medicinal products:

  • EU law requires that marketing authorisation (MA) holders are established in the EU. Consequently, MAs for the EU which are currently held by UK entities have to be transferred to EU27 entities.
  • In addition, a number of activities related to pharmacovigilance or batch release can no longer be performed in the UK, but have to be transferred to entities/persons in the EU27.

The EMA and the relevant Coordination Groups of national medicines agencies of EU Member States (the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) and the Coordination Group for Mutual Recognition and Decentralised Procedures – Veterinary (CMDv)) have issued several guidance documents on the formal steps that may have to be implemented to avoid any disruptions of supply and sale of medicinal products in the EU.

These guidance documents5 are updated on a continuous basis and reflect the questions raised by pharmaceutical companies in stakeholder meetings with the EMA. The guidance documents cover a number of possible issues relating to existing MAs, ongoing MA procedures, pharmacovigilance obligations and the supply chain (production, batch release) as a consequence of Brexit.

Generally, the required modifications on the regulatory files/authorisations have to be implemented by 30 March 2019.

Pharmaceutical companies should therefore check whether:

  • UK entities are currently MA holders for products sold in the EU.
  • Any relevant tasks relating to pharmacovigilance are performed by Qualified Persons for Pharmacovigilance6 (QPPV) in the UK.
  • Any relevant tasks related to the supply chain (such as batch release) are performed by Qualified Persons7 (QP) in the UK.

If that is the case, companies should implement the required changes in accordance with the EMA/CMDh Guidance. These issues are covered in the sections below.

(c) Centralised Marketing Authorisations

The MA issued under the 'centralised procedure' by the European Commission (EC), following the assessment of the application carried out by the EMA, allows the MA holder to offer its medicinal products throughout the EU on the basis of a single MA. According to Article 2 of Regulation 726/20048, the MA holder must be established in the EU.

  • MA holders established in the UK therefore have to transfer their centrally authorised MAs to a legal entity based in the EU27 in order to maintain the validity of such MAs.

Currently, around 2,400 central MAs and 400 centrally authorised products are held by UK legal entities (multiple MAs can be held per product). These figures account respectively for 17% of all central MAs and 45% of all centrally authorised products in the EU.9

According to the EMA Guidance, the transfer of the MA must be fully completed and implemented before 30 March 2019. The EMA expects that implementation periods will exceed six months.10 A separate transfer application has to be lodged with the EMA for each MA. However, for the purpose of facilitating the large number of transfer applications, the EMA agreed that a combined version of each required supportive document (except product information and, when applicable, mock-ups) can be created, covering all products affected.11

  • Similarly, for ongoing MA procedures with the EMA or the filing of new MA applications with the EMA, the applicant has to be changed to an entity based in the EU27 if the applicant is currently a UK entity.

(d) National Marketing Authorisations

For National Marketing Authorisations (NMA) for medicinal products granted in one, or a number of EU Member States under the so-called Mutual Recognition Procedure (MRP) and/or Decentralised Procedure (DCP), EU law requires that these NMAs must be held by EU-based legal entities.12

  • All non-UK NMAs currently held by marketing authorisation holders established in the UK therefore have to be transferred to companies in the EU27 by 30 March 2019.13

For ongoing procedures/applications for NMA, EU law provides that marketing authorisation applicants must be established in the EU.

  • Therefore, for marketing authorisation applications that are expected to receive an NMA in an EU Member State after 30 March 2019, applicants established in the UK will need to change to a non-UK applicant established in the EU27.
  • In addition, if the Reference Member State (RMS) in an ongoing DCP or MRP is the UK, applicants need to change the task of the RMS to an agency of a Member State of the EU27. The same applies for already authorised products in which the UK acted as the RMS.14

(e) Pharmacovigilance

According to EU pharmaceutical legislation, the QPPV for authorised medicinal products must reside and carry out his/her tasks in an EU Member State, and the Pharmacovigilance Master File (PSMF) also must be located within the EU.15

  • If these tasks are currently fulfilled in the UK, the respective changes on the QPPV and the location of the PSMF have to be notified to the authorities.

(f) Supply chain, including batch release/control

Brexit may also impact the supply chain. EU law requires that all batch release/control activities have to be performed by a QP within the EU.16 Furthermore, active substances or finished products manufactured in the UK will be considered imported medical products under EU law as of the withdrawal date.

Each batch of a finished product manufactured in the EU must be certified by a QP within the EU before being placed on the market. For products imported into the EU from the UK, MA holders therefore have to specify an authorised importer established in the EU, must obtain an import authorisation.17 Furthermore, such imported products manufactured in the UK have to undergo batch control at a site in the EU.

  • If the QP and/or the site for batch release/control is currently located in the UK, this has to be changed to a location established in the EU27 by submitting corresponding variations of the MA documents to the EMA (in case of centrally authorised products) or the respective national authorities in EU27 Member States (in case of national marketing authorisations).

III. Medical Devices

(a) Current To-Dos–Authorised Representatives

Under EU law, medical devices manufacturers offering their devices in the EU must either (a) have a physical location in the EU, or (b) appoint an Authorised Representative (AR) established within the EU. As of 30 March 2019, unless something more specific is agreed in the FTA, it appears that all the ARs established in the UK will no longer be operative.

If that is the case, the medical devices companies will no longer be able to rely on their ARs established in the UK and, as a result, must implement certain measures to continue selling their medical devices in the EU27 after Brexit:

  • UK medical devices manufacturers have to appoint an AR established in one of the EU27 Member States.
  • Medical devices manufacturers from 'third countries' that currently use an AR established in the UK also have to appoint a new AR established in one of the EU27 Member States.
  • Should the UK and the EU27 both require their own ARs, non-UK-based manufacturers would have to appoint an AR in the UK also.

(b) Current To-Dos–Notified Bodies and CE Markings

As of 30 March 2019, unless the future FTA provides otherwise, the "notified bodies"18 located in the UK will cease to be authorised to conduct conformity assessments and to affix CE markings. As a consequence, all the CE markings affixed by the UK notified bodies for medical devices would become void.

Companies that currently hold such certificates or that are planning to apply for a new certification have to take the necessary steps to ensure that they can continue selling their products within the EU27:

  • Medical devices manufacturers working with UK notified bodies have to:
    1. either appoint a new notified body established in one of the EU27 Member States, which would require a new conformity assessment to permit the continued CE marking of their medical devices in the EU27; or
    2. if possible, transfer the CE marking from a UK notified body to an EU27 subsidiary through the same standards body, as this should be a less burdensome alternative and would not require the applicant company to undergo the same full certification process a second time.
  • Medical devices manufacturers looking to obtain an EU certification for a new product have to:
    1. if possible, use one of the EU27 subsidiaries of the UK parent notified body, because, in principle, it should be simpler to apply for a second certification in the UK by using the same standards body; or
    2. use any EU27 notified body and appoint a new notified body within the UK for a second certification to cover the UK market.

Medical devices manufacturers already certified by an EU27 notified body will have to apply for a second certification in the UK.

(c) Status of the UK Notified Bodies

In the UK, there are currently five notified bodies.19 It is reported that these bodies together perform more than half of all conformity assessments for medical devices in the EU market.20

Most of the UK's notified bodies are already implementing various strategies to accommodate medical devices manufacturers in this transition, for example, by formally applying for designation as medical devices notified bodies in the EU27, or negotiating a retention of their capabilities and capacities as medical devices notified bodies in the UK after Brexit.

Some designated organisations, even outside the EU, are recognised as notified bodies for the purposes of medical devices certification (e.g. in Iceland, Liechtenstein and Norway, under the EEA agreement; in Switzerland and Australia through Mutual Recognition Agreements).

It is too early yet to predict with certainty what the UK's position will be, but the EC's Notice to Stakeholders of 22 January 2018 presents a scenario whereby if no action is taken to ensure continuation for conformity assessment procedures and notified bodies in the UK, the UK notified bodies would lose their status as EU notified bodies and would be removed from the EC's information system on notified organisations.21

In addition, the draft Withdrawal Agreement between the EU and the UK requires both the UK and the EU to ensure that, upon request by the certificate holders, their respective notified bodies will provide information about the holder's certification activities to another notified body without undue delay. This requirement also points to the scenario in which the companies will be required to have separate conformity certificates in the UK and the EU27.


[1] Article 122 of Draft Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community of 19 March 2018.

[2] European Council (Art. 50) guidelines on the framework for the future EU-UK relationship, 23 March 2018, para. 7.

[3] Under Article 77 of Regulation (EC) No 726/2004, only the representatives of international organisation may participate as observers in the work of the EMA if conditions determined by the European Commission are met.

[4] MHRA update to pharmaceutical companies on exit preparations, 16 January 2018.

[5] European Commission/EMA, Practical guidance for procedures related to Brexit for medicinal products for human and veterinary use within the framework of the centralised procedure, EMA/478309/2017 Rev. 1, 29 January 2018 ("EMA Guidance") and CMDh, Questions and answers related to the United Kingdom's withdrawal from the European Union with regard to national authorised medicinal products for human use, CMDh/361/2017, Rev.1, 1 December 2017 ("CMDh Guidance").

[6] A Qualified Person for Pharmacovigilance is an individual, usually an employee of a pharmaceutical company, who is personally responsible for the safety of the human pharmaceutical products marketed by that company in the EU for pharmacovigilance or batch release/control.

[7] A Qualified Person is responsible for compliance with pharmaceutical regulations regarding manufacturing, testing and release.

[8] Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.

[9] BREXIT EFPIA survey results of 8 November 2017, European Federation of Pharmaceutical Industries and Associations.

[10] No. 4 of EMA Guidance.

[11] No. 4c of EMA Guidance.

[12] Article 8(2) of Directive 2001/83/EC.

[13] No. 1 of CMDh Guidance.

[14] No. 1b of CMDh Guidance.

[15] Article 8 of Directive 2001/83/EC (QPPV) and Commission Implementing Regulation (EU) No 520/2012.

[16] Articles 51(1) (batch release) and 51(1)(b) (batch control after importation of products into the EEA) of Directive 2001/83/EC.

[17] Articles 40(3), 41 and 42 of Directive 2001/83/EC.

[18] In EU law, a "notified body" is an organisation designated by an EU country to assess the conformity of medical devices before being placed on the market. These bodies carry out tasks related to conformity assessment procedures set out in the applicable legislation, when a third party is required.

[19] British Standards Institution, SGS United Kingdom Ltd., Lloyd's Register Quality Assurance Ltd., AMTAC Certification Services Ltd. and UL International (UK) Ltd.

[20] Brexit and the impact on patient access to medicines and medical technologies, Brexit Health Alliance, Briefing of January 2018.

[21] European Commission Notice to Stakeholders Withdrawal of the United Kingdom and EU Rules in the Field of Industrial Products, DG for Internal Market, Industry, Entrepreneurship and SMEs, 22 January 2018.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Arnold & Porter
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Arnold & Porter
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions